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Abstract 
Background: Hereditary angioedema (HAE) is a potentially life-threatening, bradykinin-mediated disease, often mis-
diagnosed and under-treated, with long diagnostic delays. There are limited real-world data on best-practice manage-
ment of HAE in the UK.
Objectives: To characterize the clinical profile, management and outcomes of patients with HAE type I and II from 
three specialist centres in the UK using data from the Icatibant Outcome Survey (IOS; Shire, Zug, Switzerland), an 
international observational study monitoring safety and effectiveness of icatibant, a selective bradykinin B2 receptor 
antagonist.
Methods: We performed retrospective analyses of IOS data for patients with HAE type I and II from three centres in 
the UK and compared UK data with pooled IOS data from 10 countries (48 centres).
Results: Analyses included 73 UK and 579 non-UK patients with HAE type I or II. Median diagnostic delay was 6.2 
and 5.9 years, respectively. Analysis of data collected from February 2008 to July 2016 included 286 icatibant-treated 
attacks in 58 UK patients and 2553 icatibant-treated attacks in 436 non-UK patients (median of 3.0 attacks per patient 
in both groups). More attacks were treated by icatibant self-administration in UK patients (95.8%) than in non-UK 
patients (86.8%, p < 0.001). Time to icatibant treatment, time to resolution and attack duration were not significantly 
different in the UK versus non-UK patients.
Conclusion: UK patients from the specialist centres studied report similar diagnostic delay and similar icatibant 
treatment outcomes to their non-UK counterparts. However, improvements in the timely diagnosis of HAE are still 
required.
Trial registration ClinicalTrials.gov NCT01034969
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Background
Hereditary angioedema (HAE) due to C1 inhibitor 
(C1-INH) deficiency is a rare autosomal dominant dis-
ease caused by mutations in the SERPING1 gene result-
ing in reduced levels (type I) or dysfunction (type II) of 
C1-INH. HAE type I and II attacks are characterized 
by recurrent swelling, commonly occurring in the skin, 
abdomen and larynx, which can be severe and debilitat-
ing [1, 2]. In the UK, there are an estimated 1500 people 
with C1-INH deficiency, many of whom are undiagnosed 
[3]. A number of consensus international and UK guide-
lines regarding the diagnosis and management of HAE 
have been published [4–9]. However, the rarity of HAE 
means that non-specialist physicians are often unfamiliar 
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with these conditions and patient management is usu-
ally conducted in coordination with tertiary centres, with 
particular emphasis on patient self-care [3, 9].
In the UK, intravenously administered plasma-derived 
C1-INH  (Berinert®,  Cinryze®), recombinant C1-INH 
 (Ruconest®) and the subcutaneously administered 
bradykinin receptor antagonist icatibant  (Firazyr®) are 
licensed and effective for the treatment of acute attacks 
of HAE and are now commissioned nationally for home-
based self-administration [10–15]. Following the initial 
approval of icatibant within Europe, the Icatibant Out-
come Survey (IOS), a real-world patient registry docu-
menting the clinical outcomes of patients treated with 
icatibant, was established to fulfil a European medicines 
agency post-marketing surveillance safety requirement. 
A number of clinical registries and surveys for HAE 
have been conducted in several countries [16–19], which 
may be used to support quality improvement activities. 
Although a recent UK national audit has helped to char-
acterize the experience of patients with HAE [20], there 
is a relative paucity of UK data to help improve clinical 
practice and better understand the burden of disease.
This report summarizes observational UK data col-
lected within the first 6  years of IOS (March 2010–July 
2016) to characterize the clinical profile, management 
and outcomes of patients with HAE. These data could be 
used as an unofficial ‘benchmark’ of standards from three 
major centres within the UK that offer specialist manage-
ment and up-to-date treatment protocols. In addition, 
data from the UK are compared with other IOS coun-
tries, with the aim of identifying potential areas for qual-
ity improvements.
Methods
Study design and patients
IOS (NCT01034969) is a prospective, international, 
observational study; study methodology has been pub-
lished elsewhere [21]. The registry enrols patients with 
C1-INH deficiency (HAE types I and II), consistent with 
the European approval conditions for icatibant, but any 
patient prescribed subcutaneous icatibant treatment is 
eligible for inclusion. IOS is conducted in accordance 
with the Declaration of Helsinki and the international 
conference on harmonisation good clinical practice. 
Approval was obtained from ethics committees and/or 
local health authorities at all centres. Written, informed 
consent was obtained from all enrolled patients aged 
≥ 18 years (≥ 16 years in the UK); consent was provided 
by parents/legal guardians for patients aged < 18  years 
(< 16 years in the UK).
The analyses described herein are based on IOS data 
collected between July 2009 and July 2016 for patients 
with HAE type I or II; patients with other forms of 
angioedema were excluded from this analysis. Retrospec-
tive data for attacks recorded prior to IOS enrolment 
were also collected, dating back to February 2008. During 
this period, a total of 51 centres in 11 countries contrib-
uted data for this analysis: Austria (n = 1), Brazil (n = 1), 
Germany (n = 7), Denmark (n = 1), Spain (n = 9), France 
(n = 17), Greece (n = 2), Israel (n = 4), Italy (n = 5), Swe-
den (n = 1) and the UK (n = 3). We also include a separate 
description of seven patients with acquired angioedema 
(AAE) due to C1-INH deficiency for this period from the 
UK sample, including one patient who was treated with 
icatibant for acute attacks (unlicensed indication).
Patient demographics and characteristics were 
recorded at enrolment (IOS entry [baseline]), including 
information on HAE attacks (including icatibant-treated) 
before IOS entry. Information relating to physical exami-
nation, icatibant treatment, concomitant medications 
and adverse events was collected at enrolment and at 
routine visits, recommended every 6  months thereaf-
ter. Data for attacks treated with icatibant or untreated 
attacks were recorded, including rescue medication and 
long-term prophylaxis usage; data for attacks treated 
with other products are not collected in IOS. For each 
icatibant-treated HAE attack, data were collected for 
time to treatment (time between the start of the attack 
and the first icatibant injection), duration of attack (time 
between onset of attack and complete resolution of 
symptoms) and time to resolution (time between first 
icatibant injection and complete resolution of symptoms) 
(Fig.  1). Data recorded for untreated attacks included 
frequency and duration of untreated attacks in the prior 
12 months and potential reasons for non-treatment. 
The IOS protocol does not specify how patients should 
record attacks. Patients used several methods to record 
attacks, including diaries, evaluation forms and, in some 
cases, reporting attacks contemporaneously to specialist 
nurses. Self-administration of treatment included admin-
istration by family members or the patient, according to 
national prescribing information, after training in subcu-







Time to resolutionTime to treatment
Duration of attack
Fig. 1 Schematic of effectiveness measures used in the Icatibant 
Outcome Survey
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Attack severity was described by patients and was veri-
fied by a healthcare professional at routine visits. Severity 
was classified as: none (absence of symptoms); mild (mild 
interference with daily activities); moderate (moderate 
interference with daily activities and no other treatment 
required; severe (severe interference with daily activities 
and with or without other treatment); and very severe 
(very severe interference with daily activities and other 
treatment required) [22].
Statistical analyses
Results of UK versus non-UK populations were com-
pared. A mixed-model analysis of repeated measures 
(Proc Mixed; SAS Institute, Cary, NC, USA) was used 
to compare time to treatment, time to resolution and 
duration of attack. The Chi squared test was used for the 
comparison of dichotomous data, with a statistical signif-
icance level of alpha = 0.05. Data are presented as median 
(interquartile range [IQR]) or mean (standard deviation 
[SD]), unless otherwise specified.
Results
Patient characteristics
Between July 2009 and July 2016, 652 patients diagnosed 
with HAE type I or II were entered into the IOS database. 
Of these, 73 patients were from three centres in the UK 
(enrolled from March 2010 onwards) and 579 patients 
were from 48 centres outside the UK. Approximately 60% 
of patients in both UK and non-UK groups were female. 
Median patient age at extract was 42.2 and 43.3 years for 
UK and non-UK patients, respectively. Patient demo-
graphics and baseline characteristics are presented in 
Table 1. In the UK, one patient received icatibant under 
the age of 18 years (two icatibant injections, one each for 
two separate attacks at 17.6 and 17.8 years). Outside the 
UK, five patients received icatibant injections under the 
age of 18 years (range 16.2–17.9 years). Of these five non-
UK patients, two patients each received a single icatibant 
injection, one patient received three icatibant injections 
for three separate attacks, one patient received four icati-
bant injections for four separate attacks and one patient 
received ten icatibant injections for ten separate attacks.
Socioeconomic data
Employment status for UK and non-UK patients at 
IOS entry is shown in Table  1. In the UK, a signifi-
cantly higher proportion of patients were employed or 
self-employed compared with non-UK patients; 53/73 
(72.6%) versus 233/419 (55.6%); p = 0.0111. The propor-
tion of students among the UK and non-UK patients was 
similar: 8/73 (11.0%) and 53/419 (12.6%), respectively. 
More patients in the UK missed work or education prior 
to IOS compared with non-UK patients (63.3% versus 
37.6%, respectively; p = 0.009) and during the IOS obser-
vation period (54.9% versus 24.9% respectively, p < 0.001) 
(Fig. 2). The proportion of patients missing days of work 
or education improved in the non-UK patients during the 
IOS observation period (decreasing from 37.6 to 24.9%) 
The proportion of patients missing days of work or edu-
cation showed a non-significant trend to improvement 
in the UK during the IOS observation period (decreas-
ing from 63.3 to 54.9%, p = 0.060); however the reduction 
was seen only in patients reporting absences of ≤ 7 days. 
More patients in the UK required hospitalisation prior 
Table 1 Patient demographics and baseline characteristics
HAE hereditary angioedema, IQR interquartile range, SD standard deviation
a n = 73
b n = 579
c n = 58
d n = 497
e n = 70
f n = 535
g n = 486
h Patients could have more than one employment status (UK sample n = 73, 
non-UK patients n = 419)





Age at extract, years
 Mean (SD) 42.9 (14.7)a 45.1 (15.2)b
 Median (range) 42.2 (18–82)a 43.3 (6–86)b
Gender, n (%)
 Male 29 (39.7) 235 (40.6)
 Female 44 (60.3) 344 (59.4)
Age at first symptoms, years
 Mean (SD) 11.3 (9.5)c 14.1 (11.2)d
 Median (IQR) 10.0 (5.0, 16.0)c 13.0 (6.0, 19.0)d
Age at diagnosis, years
 Mean (SD) 21.5 (12.7)e 24.6 (15.9)f
 Median (IQR) 18.9 (12.6, 30.0)e 21.0 (13.2, 34.2)f
Delay between first symptoms and diagnosis, years
 Mean (SD) 9.5 (13.9)c 10.5 (13.6)g
 Median (IQR) 6.2 (0.0, 17.5)c 5.9 (0.4, 17.6)g
Employment status, n (%)h
 Employee 46 (63.0) 218 (52.0)
 Self-employed 7 (9.6) 15 (3.6)
 Homemaker 3 (4.1) 20 (4.8)
 Leave of absence/sabbatical 1 (1.4) 2 (0.5)
 Pre-school 0 4 (1.0)
 Retired 3 (4.1) 42 (10.0)
 Student 8 (11.0) 53 (12.6)
 Unemployed 4 (5.5) 34 (8.1)
 Other/unknown 4 (5.5) 43 (10.3)
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to IOS compared with non-UK patients (20.6% versus 
12.8%, respectively; p = 0.037), however no difference 
in rates of hospitalisation during the IOS observation 
period between UK and non-UK patients was observed 
(p = 0.696) (Fig.  3). However, within the UK the rate of 
hospitalisations prior to IOS compared to the IOS obser-
vation period showed a trend to improvement but this 
did not reach statistical significance (p = 0.098).
Use of long-term prophylaxis
In UK and non-UK patients, respectively, ongoing long-
term prophylaxis use at IOS entry and during the fol-
low-up period was 75.3% (55/73) and 44.4% (257/579). 
Attenuated androgens (danazol, stanozolol and oxan-
drolone) were the most commonly used ongoing long-
term prophylaxis medication (at IOS entry and during 
the follow-up period) by both UK and non-UK patients 
(accounting for 59.9 and 66.9% of usage, respectively). 
In the UK, attenuated androgens were used as ongoing 
long-term prophylaxis in 54.5% (18/33) of patients from 
the Barts Health NHS Trust, London; 71.4% (10/14) of 
patients from the Central Manchester University Hospi-
tal NHS Foundation Trust, Manchester and 62.5% (5/8) 
of patients from Plymouth Hospital NHS Trust. Other 
ongoing long-term prophylactic agents used in the UK 
overall were C1-INH (7.3%; 4/55) and tranexamic acid 
(23.6%, 13/55).
Delay in diagnosis
Median age at diagnosis of HAE type I or II was 
18.9 years for the UK patients and 21.0 years for non-UK 
patients, with a median delay between first symptoms 
and diagnosis of 6.2  and 5.9 years, respectively (Table 1). 
Of 58 patients in the UK with available data, 36 (62.1%) 
patients experienced a delay in diagnosis of ≥ 2  years, 
with 23 (39.7%) patients having a delay of ≥ 10  years 
(Fig.  4). There was a clear biphasic distribution in time 
from symptoms to diagnosis.
Treatment of HAE attacks with icatibant
Attack rate
Among 73 patients in the UK, 58 (79.5%) had reported 
at least one attack treated with icatibant, with a total of 






































Fig. 2 Proportion of the UK and non-UK IOS patients with days of 
missed work or education prior to IOS entry and during the IOS 
observation period. For the UK and non-UK patients, respectively, 
n = 49 and n = 125 for the period before IOS entry and n = 51 and 
n = 201 for the IOS follow-up period. BL baseline (12 months prior 
to IOS entry), FU follow-up, IOS Icatibant Outcome Survey. aNon-UK 
countries are Austria, Brazil, Denmark, France, Germany, Greece, Israel, 







































Fig. 3 Proportion of the UK and non-UK IOS patients hospitalized at 
baseline (prior to IOS entry) and during IOS observation. For the UK 
and non-UK patients, respectively, n = 68 and n = 367 for the period 
before IOS entry and n = 52 and n = 399 for the IOS follow-up period. 
BL baseline (12 months prior to IOS entry), FU follow-up, IOS Icatibant 
Outcome Survey. aNon-UK countries are Austria, Brazil, Denmark, 
France, Germany, Greece, Israel, Italy, Spain and Sweden























n = 6 n = 7
n = 23
Fig. 4 Proportion of HAE patients in the UK sample with a delay in 
diagnosis. HAE hereditary angioedema. n = 58
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from 31 patients from the Barts Health NHS Trust, Lon-
don, 16 patients from the Central Manchester Univer-
sity Hospital NHS Foundation Trust, Manchester and 11 
patients from the Plymouth Hospitals NHS Trust, Plym-
outh (Table  2). A total of 2553 icatibant-treated attacks 
were reported for 436/579 (75.3%) patients in countries 
outside the UK. A median of 3.0 attacks per patient were 
treated with icatibant in both the UK and outside the UK 
(Table 3).
Icatibant‑treated versus untreated attacks
In total, 854 attacks were recorded after IOS entry 
for the 73 UK patients. Of these, 286 (33.5%) attacks 
were treated with icatibant and 568 (66.5%) remained 
untreated. As IOS is an icatibant registry, data for 
attacks treated with C1-INH were not recorded. For 
non-UK patients, 5423 attacks were recorded after IOS 
entry, with 2553 (47.1%) attacks treated with icatibant 
and 2870 (52.9%) attacks not treated with any treat-
ment. In UK patients, the median number of untreated 
attacks per patient was the same (2.0) in the IOS obser-
vation period (data collected at routine visits) as in the 
period prior to IOS entry (data collected at baseline) 
(Table 3). For non-UK patients, the median number of 
untreated attacks per patient was lower (1.0 versus 2.0, 
respectively) in the IOS observation period than in the 
period prior to IOS entry. Since C1-INH-treated attacks 
were not recorded, no conclusion can be drawn as to 
overall percentages. However, it remains clear that a 
substantial numbers of attacks are untreated and that in 
the UK, these outnumber those treated with icatibant 
by almost 2–1. Although we do not have data on sever-
ity or complete data on possible reasons for non-treat-
ment, the duration of untreated attacks, both prior to 
IOS enrolment (median 72 h for both UK and non-UK 
patients) and IOS follow-up period (72 versus 79 h for 
the UK and non-UK patients, respectively) is substan-
tially longer than for treated attacks (9.0 versus 8.6 h; 
Table 4).
Severity of attacks
In the UK, 65.5% (279/426) of attacks before treatment 
were classified (where data were available) as severe/very 
severe; 26.1% (111/426) as moderate; and 8.5% (36/426) 
as mild or very mild. For non-UK patients, attack sever-
ity before treatment was classified as severe/very severe, 
53.3% (1441/2704 attacks); moderate, 37.2% (1005/2704 
attacks); and mild or very mild, 9.5% (258/2704 attacks). 
No difference in attack severity was observed between 
UK and non-UK patients (p = 0.1724).
Table 2 HAE type I or II attacks treated with icatibant in the UK sample
HAE hereditary angioedema, IOS Icatibant Outcome Survey




sity hospital NHS foundation 
trust, Manchester
N = 16





Patients, n Attacks, n Patients, n Attacks, n Patients, n Attacks, n Patients, n Attacks, n
Before IOS entry 23 40 11 84 11 21 45 145
After IOS entry 24 146 12 124 5 20 41 290
Total 31 186 16 208 11 41 58 435
Table 3 Comparison of HAE attacks treated with icatibant 
and untreated attacks
HAE hereditary angioedema, IOS Icatibant Outcome Survey, IQR interquartile 
range, SD standard deviation
a Attacks in year prior to IOS entry and through the IOS observation period
b Untreated attacks were defined as attacks not treated with icatibant or any 
other treatment
c 19 patients had no untreated attacks
d 114 patients had no untreated attacks
e 22 patients had no untreated attacks
f 150 patients had no untreated attacks







 Patients treated with icatibant, n 58 436
 Attacks treated with icatibant per patient
  Mean (SD) 7.5 (12.8) 7.6 (12.5)
  Median (IQR) 3.0 (1.0, 6.0) 3.0 (1.0, 8.0)
Untreated attacks in year prior to IOS  entryb
 Patients with at least one untreated attack, n 46c 219d
 Untreated attacks per patient
  Mean (SD) 8.5 (16.8) 7.4 (14.0)
  Median (IQR) 2.0 (0, 5.0) 2.0 (0, 8.0)
Untreated attacks in the IOS observation  perioda
 Patients with at least one untreated attack, n 30e 198f
 Untreated attacks per patient
  Mean (SD) 10.9 (23.2) 8.2 (17.3)
  Median (IQR) 2.0 (0.0, 8.0) 1.0 (0, 8.0)
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Use of icatibant self‑administration
Of the attacks treated with icatibant, the majority were 
treated by self-administration both inside and outside the 
UK (95.8% versus 86.8%, respectively) (Fig.  5) with the 
rate of self-administration in the UK significantly higher 
(p < 0.001) compared to non-UK patients. Healthcare 
professionals administered icatibant for first attacks in 
around one-third of UK and non-UK patients in the IOS 
observation period (16/57 [28.1%] and 133/366 [36.3%], 
respectively). The mode of icatibant administration for 
the first five attacks for UK patients is shown in Fig. 6.
Time to icatibant treatment, time to resolution and attack 
duration
Time to treatment with icatibant, time to resolution 
and duration of attack were not significantly different 
in the UK compared with non-UK patients, although 
there was a trend to earlier treatment in UK patients, 
p = 0.0632, p = 0.2774 and p = 0.1022, respectively 
(Table 4, Fig. 7).
Use of C1‑INH rescue
In the UK, excluding one outlier with a very atypical 
pattern of use (described below), C1-INH was used as 
rescue medication in 12.7% of icatibant-treated attacks 
(48/378 attacks in 15/57 patients) compared with 9.2% 
of icatibant-treated attacks (304/3306 attacks in 86/436 
patients) in non-UK patients.
Table 4 Time to treatment, time to resolution and duration of icatibant-treated HAE attacks
HAE hereditary angioedema, IQR interquartile range, n number of evaluable attacks, SD standard deviation
a Attacks with complete data for time to treatment, time to complete resolution and attack duration, excluding attacks treated > 100 h after attack onset
b Mixed-model analysis of repeated measures comparing the UK versus non-UK IOS datasets
c Time between the start of the attack and the first icatibant injection
d Time between first injection of icatibant and complete resolution of symptoms
e Time between start of attack and complete resolution of symptoms






na Mean (SD) Median (IQR) na Mean (SD) Median (IQR)
Time from attack onset to treatment,  hc 222 2.9 (4.8) 0.8 (0.4, 3.0) 1120 3.9 (7.3) 1.3 (0.5, 4.0) 0.0632
Time to complete symptom resolution,  hd 222 10.5 (14.1) 6.0 (1.3, 14.0) 1120 11.8 (16.1) 5.8 (2.0, 14.1) 0.2774


















4.2 n = 18
95.8
n = 410 86.8
n = 2269
13.2 n = 346
Fig. 5 Proportion of HAE attacks treated with icatibant by self-admin-
istration or administration by HCPs per attack in the UK and non-UK 
patients. HAE hereditary angioedema, HCP healthcare professional
















HCP administration (n = 39)





















Fig. 6 Administration of icatibant for first five HAE attacks in UK 
patients. HCP health care professional. aThe remaining two HCP-
administered instances of icatibant occurred during attack 14 (9.1%) 
and attack 19 (11.1%). Family member administrations are included 
in the self-administration category. All non–self-administrations are 
included in the HCP category. Missing attack dates are not taken into 
account
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Clinical experience: patient with high icatibant reinjection 
and C1‑INH rescue medication usage
Further analysis of the pattern of icatibant usage revealed 
that one patient in the UK had a high rate of icatibant 
reinjection combined with high usage of C1-INH rescue 
medication. This 50-year-old man with HAE type I self-
administered icatibant for 57 HAE attacks (very severe, 
n = 12; severe, n = 39; and moderate, n = 6) between 
22 October 2009 and 25 October 2014. Approximately 
half (27/57) of these attacks were treated with a second 
injection of icatibant and 86.0% (49/57) with C1-INH 
rescue medication. The median (IQR) time to first icati-
bant injection was 0.5 (0.5–1.0)  h, median (IQR) time 
to complete resolution was 1.0 (0.5–9.5)  h and median 
(IQR) duration of attack was 3.5 (1.0–11.0)  h. Median 
(IQR) time between first and second icatibant injection 
was 9.0 (6.0–12.0) h and the median (IQR) time between 
second injection and complete resolution was 0.5 (0.5–
0.5) h. During the treatment period the patient was under 
intense psychological stress and had frequent bouts of 
confirmed abdominal angioedema (Fig. 8). The majority 
of icatibant-treated attacks (68.4%; 39/57) were abdomi-
nal. The patient was receiving long-term danazol prophy-
laxis at attack onset for 49.1% (28/57) of icatibant-treated 
attacks. However, in spring 2011 prophylaxis with dana-
zol became contraindicated owing to the development 
of abnormal liver function tests, hyperlipidaemia and 
weight gain. The patient initiated long-term prophylaxis 
with C1-INH in April 2011 and has reported only three 




0–1 >1–≤2 >2–≤5 >5
0–1 >1–≤2 >2–≤5 >5
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bp = 0.4267 UK patients versus non-UK patients
bp = 0.8440 UK patients versus non-UK patients
bp = 0.4425 UK patients versus non-UK patients
Fig. 7 Proportion of icatibant-treated HAE attacks (with complete 
data for time to treatment, time to resolution and attack duration) in 
UK patients and non-UK patients according to a time to treatment, b 
time to symptom resolution and c duration of attack. HAE hereditary 
angioedema, Time to treatment time between the start of the attack 
and the first icatibant injection, Time to resolution time between first 
injection of icatibant and complete resolution of symptoms, Attack 
duration time between start of attack and complete resolution of 
symptoms. aNon-UK countries are Austria, Brazil, Denmark, France, 
Germany, Greece, Israel, Italy, Spain and Sweden. bGeneralized linear 
model for repeated measures
Fig. 8 Abdominal computed tomography image obtained at admis-
sion of a 47-year-old male patient with HAE type I with abdominal 
angioedema
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Acquired angioedema
Seven patients from the UK and 34 non-UK patients had 
a diagnosis of AAE due to C1-INH deficiency. Icatibant is 
not currently licensed for use in patients with AAE due to 
C1-INH deficiency and these patients were not included 
in the analysis described above. However, for complete-
ness of the UK dataset, we include a brief description of 
the seven UK patients in Table 5 [23].
Discussion
IOS has allowed the follow-up of patients with HAE 
type I/II in the UK and centres across Europe, the Mid-
dle East and South America. These data from three UK 
centres suggest that HAE remains under-recognized 
in the UK, as shown by long diagnostic delays. Whilst 
some patients were diagnosed prior to first symptoms 
(presumably based on family history) or at the time of or 
soon after first symptoms, others experienced very long 
delays, with consequent increased risk of avoidable mor-
tality and morbidity. The delay in diagnosis in the UK 
(n = 73) was comparable to that in non-UK countries, 
which supersedes the previously reported trend from 
a smaller IOS UK patient population (n = 12) [24]. The 
delay in diagnosis in the UK was shorter than the delay 
in diagnosis recently reported in a UK National Audit of 
HAE; however this may be explained by differences in 
methodology, as the authors of the UK National Audit 
excluded all patients who received diagnoses before 
experiencing symptoms [20]. The overarching message 
from all these studies is that delay in diagnosis is highly 
variable; a recent IOS analysis found approximately 50% 
of patients with HAE type I/II had received a prior misdi-
agnosis, most commonly allergic angioedema or appen-
dicitis [25]. Increased awareness of HAE could reduce 
time to diagnosis and permit appropriate management of 
the condition, thus reducing the morbidity and mortality 
associated with undiagnosed HAE [26].
Self-administration of HAE treatment at home offers 
the potential for earlier treatment and symptom control 
[21], reducing the impact of HAE on physical, social and 
economic well-being and reducing healthcare resource 
use [8, 27, 28]. The UK patients included a higher propor-
tion of attacks treated by self-administration compared 
with non-UK patients (95.8% versus 86.8%, respec-
tively). This may partially be due to the later enrolment 
of patients in the UK, with 66/73 (90.4%) patients joining 
the study in 2011 or later, compared with a larger num-
ber of patients in Europe (177/579 [30.6%]) who enrolled 
up to 2  years prior to the 2011 change in indication to 
include self-administration. Importantly, each of our 
UK centres in IOS is a strong advocate of home therapy 
and patient empowerment, in accordance with UK gov-
ernment policy and home therapy guidance [3, 7, 10]. 
There is long-standing experience of treating and training 
patients for self-administration in the UK, compared with 
more recent experience in some other European coun-
tries [15, 29]. This is greatly facilitated by the availability 
of immunology specialist nurses who develop consider-
able expertise in self-administration training and patient 
support [14, 29, 30]. Although a higher proportion of 
UK patients self-administered icatibant compared with 
non-UK patients, the proportion of first attacks treated 
by self-administration was similar for the UK sample and 
non-UK patients (71.9% versus 63.7%, respectively). It 
is recommended that the first dose of icatibant is given 
under the supervision of a healthcare professional to 
ensure adequate training [12] and allow monitoring of 
tolerability to the drug immediately after administration. 
However, the need for professional supervision can be a 
barrier to accessing treatment and therefore remains a 
recommendation rather than a requirement. These IOS 
data support our clinical experience that patients toler-
ate icatibant well and, with encouragement and support, 
rarely require more than one training session. Moreover, 
Table 5 UK patients with acquired angioedema
HCP healthcare professional, IOS Icatibant Outcome Survey
a July 2009 to July 2016
Patient no. Gender Age at IOS enrolment, 
years
Icatibant-treated angi-





1 Male 50.5 53 3 51
2 Male 63.1 27 6 22
3 Female 49.7 2 1 1
4 Male 70.9 1 – 1
5 Female 28.6 0 – –
6 Female 59.8 0 – –
7 Female 38.4 0 – –
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the ease of use of icatibant has enabled a greater propor-
tion of patients to self-administer treatment for HAE 
attacks than is possible with C1-INH treatment, which 
requires intravenous access.
Time to treatment, time to resolution and duration of 
attack were not significantly different in the UK com-
pared with non-UK patients. Previously, using a data 
extract of April 2015 (presented at UK PIN meeting 
2015), we had reported that UK IOS patients experience 
a significantly shorter time to treatment, time to resolu-
tion and attack duration than patients from other IOS 
countries. However, the July 2016 data presented herein 
clearly show this gap has closed, and a recent country 
comparison of IOS data provides additional information 
regarding regional variations in both delay in diagnosis 
and icatibant use across six EU member states [31]. Pre-
vious IOS analyses have demonstrated that earlier treat-
ment can reduce both overall attack duration and time to 
resolution [21].
Patients with HAE suffer impaired quality of life 
and incapacity, with time away from school, work, 
social events and family life, and reduced productiv-
ity [2, 32–39]. A higher proportion of the UK patients 
were employed or in education compared with non-UK 
patients. In the UK, a higher percentage (72.6%) were 
employed or self-employed compared with the UK 
national audit of HAE (48% in paid employment) [20]. 
As IOS is an icatibant registry, it may be that factors that 
lead to icatibant prescription result in a degree of selec-
tion bias, thereby giving rise to the differences between 
this population and the wider group of UK patients with 
HAE. However, the data could also be consistent with 
the early adoption of icatibant by the specialist centres 
studied and the inclusion of data on patients after 2013, 
when barriers to icatibant prescription were relaxed in 
the UK following adoption of a policy of central fund-
ing [8]. Patients in the UK missed more time from work 
owing to HAE than non-UK patients. Despite needing to 
miss more work for HAE attacks, a higher percentage of 
UK patients were able to maintain employment, perhaps 
because more patients self-treated with icatibant. This 
suggests that an effective self-administered treatment 
for angioedema attacks may be an important element in 
enabling patients to stay in work [8]. For example, one 
of the patients with AAE due to C1-INH deficiency had 
experienced significant employment difficulties that were 
resolved once they had access to icatibant at home and 
at work. The proportion of patients with no HAE-related 
time off work improved after inclusion in IOS. How-
ever, there was no improvement in those with high levels 
(> 7 days per annum) of HAE-related work absenteeism, 
suggesting that additional measures are required for this 
group.
Patients in IOS were managed according to routine 
clinical practice, providing a comprehensive and an 
accurate ‘real-world’ description of HAE patients with 
C1-INH deficiency at three major NHS-funded spe-
cialist centres. This prospective registry included only 
patients who were prescribed icatibant. Factors influenc-
ing icatibant prescription have not been formally charac-
terized, but may include previous treatment experience 
and training, quality of venous access, attack frequency, 
patient preference, religious beliefs (concerning blood 
products) and funding decisions (HJ Longhurst, personal 
communication). These factors may have an impact on 
the generalizability of the results. In addition, UK data 
were geographically limited to three large, specialist HAE 
centres in London, Manchester and Plymouth; therefore, 
referral bias is inevitable, and data may not be repre-
sentative of the wider UK experience (UK patients rep-
resented approximately 3.5% of the UK HAE population). 
We believe that continued national commissioning will 
reduce inequalities of access to treatment and may allow 
wider access to icatibant in the future.
Other limitations of the analyses, common to most 
observational studies, include: only patients with avail-
able data are analysed; missing data for some endpoints; 
the variable length of patient follow-up; and potential 
variability of data collection methodology for attacks 
occurring prior to IOS entry and during the IOS obser-
vational period. In addition, attack severity was described 
by the patients, therefore, may have been subjective, and 
a new attack or a relapse of a previous attack were indis-
tinguishable. Furthermore, patients who self-adminis-
ter icatibant treatment may not follow recommended 
practice, despite receiving training, and the response 
to icatibant may vary according to patient practice. The 
case we described of a patient with very high reinjection 
and C1-INH rescue use demonstrates that patients’ may 
develop different treatment practices and highlights that 
physicians should carefully monitor patients’ use of treat-
ment. However, occasional use of icatibant as a ‘hold-
ing’ treatment in patients who routinely use C1-INH for 
very frequent attacks can, in our experience, be useful in 
immediately life-threatening situations or where access 
to C1-INH is likely to be subject to unacceptable delay.
Conclusions
Data from IOS have helped characterize the experience 
of HAE patients at three UK centres. Our findings sug-
gest that availability of icatibant treatment may have 
encouraged patients to become more involved in their 
care through self-administration, with improvement in 
some outcomes such as increased rate of treatment for 
potentially debilitating attacks and HAE-related time 
off work or study. Compared with their non-UK peers, a 
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higher proportion of UK patients were in work or study-
ing. Those using icatibant reported less time off work 
than their non-UK counterparts. Ultimately, we believe 
that HAE management in the UK should focus on the 
maintenance of wider patient social and physical func-
tioning. Improvements are required to further reduce the 
unacceptable diagnostic delay and to address the problem 
of work absenteeism in those requiring more than 7 days 
off work. The latter may require a ‘whole of life’ approach 
to disability prevention.
We anticipate publishing a UK IOS update every 
3–5 years to help establish benchmarking standards and 
inform improvements to the health and quality of life in 
individuals with C1-INH deficiency.
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